In a recent update from Cantor Fitzgerald, analyst Kristen Kluska has maintained an "Overweight" rating on Sarepta Therapeutics (SRPT, Financial) while significantly lowering the price target. The new price target is set at USD 81.00, a 50.31% decrease from the previous target of USD 163.00.
This adjustment reflects notable revisions in the analyst's outlook projections for Sarepta Therapeutics (SRPT, Financial). Despite the substantial decrease in the price target, the "Overweight" rating suggests that Cantor Fitzgerald still sees potential for the stock, even as expectations have been recalibrated.
Investors and stakeholders in Sarepta Therapeutics (SRPT, Financial) should take note of this updated analysis, which may influence trading decisions as the market assimilates these new insights.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for Sarepta Therapeutics Inc (SRPT, Financial) is $146.30 with a high estimate of $209.00 and a low estimate of $70.00. The average target implies an upside of 281.30% from the current price of $38.37. More detailed estimate data can be found on the Sarepta Therapeutics Inc (SRPT) Forecast page.
Based on the consensus recommendation from 25 brokerage firms, Sarepta Therapeutics Inc's (SRPT, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Sarepta Therapeutics Inc (SRPT, Financial) in one year is $218.09, suggesting a upside of 468.39% from the current price of $38.37. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Sarepta Therapeutics Inc (SRPT) Summary page.
